LEADER 01056nam0-22003131i-450- 001 990006856600403321 005 20090716131327.0 035 $a000685660 035 $aFED01000685660 035 $a(Aleph)000685660FED01 035 $a000685660 100 $a20010426d--------km-y0itay50------ba 101 0 $aita 105 $ay-------001yy 200 1 $aFirm-level evidence on productivity differentials, turnover, and exports in Taiwanese manufacturing$fBee Yan Aw,Xiaomin Chen and Mark J. Roberts. 210 $aMilano$cFondazione Eni$d1997 215 $a50 p.$d21 cm 225 1 $aNote di lavoro della Fondazione ENI Enrico Mattei$v69 676 $a338.951249 700 1$aAw,$bBee Yan$0253348 702 1$aChen,$bXiaomin 702 1$aRoberts,$bMark J. 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990006856600403321 952 $aCOLLEZ. 1703 (69)$b31424$fFSPBC 959 $aFSPBC 996 $aFirm-level evidence on productivity differentials, turnover, and exports in Taiwanese manufacturing$9302194 997 $aUNINA LEADER 01840nam 2200373 450 001 9910597915403321 005 20230220214134.0 035 $a(CKB)4920000000094882 035 $a(NjHacI)994920000000094882 035 $a(EXLCZ)994920000000094882 100 $a20230220d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMarine Compounds and Cancer /$fedited by Friedemann Honecker, Sergey A. Dyshlovoy 210 1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2018. 215 $a1 online resource (v, 110 pages) 311 $a3-03842-765-9 330 $aThe very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development. 606 $aCancer$xRadiotherapy 606 $aMarine toxins 615 0$aCancer$xRadiotherapy. 615 0$aMarine toxins. 676 $a615.945 702 $aHonecker$b Friedemann 702 $aDyshlovoy$b Sergey A. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910597915403321 996 $aMarine Compounds and Cancer$92947621 997 $aUNINA